Associated Papers
Actionable Mutations and Survival Rates in Non-Small Cell Lung Cancer.
Al-Qaisi TS et al.
World Journal of Oncology, 2025
Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme.
Sosinsky A et al.
Nature Medicine, 2024
38200255 (PubMed )
Supplement: 41591_2023_2682_MOESM3_ESM.xlsx › Table_S1
Genetic polymorphisms as non-modifiable susceptibility factors to laryngeal cancer.
Escalante P et al.
Bioscience Reports, 2020
32338278 (PubMed )
Supplement: BSR-2019-1188_supp.pdf
Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations.
Nishimura T et al.
Frontiers in Oncology, 2020
32983988 (PubMed )
Supplement: Data_Sheet_2.xlsx › AZ015
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.
Alaoui-Jamali MA et al.
Frontiers in Genetics, 2015
25699077 (PubMed )
Supplement: Table1.PDF
Select a paper to view details